Q-omics provides the consensus-scored TENM4 profile across patient tissues and cancer cell-line models. TENM4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TENM4 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, TENM4 RNA expression shows 17,893 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where TENM4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TENM4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TENM4 survival associations across molecular data types. TENM4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TENM4 RNA expression–survival associations across cancer types. High TENM4 expression shows unfavorable associations in UVM, STAD and KIRP, but favorable associations in SCLC, HNSC and THCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TENM4 RNA expression.
This table summarizes TENM4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TENM4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TENM4 shows lower tumor expression in THCA and higher tumor expression in HNSC, LUAD, BLCA, COAD and LUSC. The HNSC box plot shows higher TENM4 RNA expression in tumor versus normal tissue (log2 FC = +1.259, t-test p < 0.001).
This table shows molecular features associated with TENM4 in patient tissues and cancer cell lines. In patient samples, TENM4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TENM4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
